Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing an additional cardiovascular benefit beyond weight and glucose effects.
Key findingSystematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing
What the researchers found
Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing an additional cardiovascular benefit beyond weight and glucose effects.
Why it matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The numbers in context
Meta-analysis included studies from database inception through July 2024. Used random-effects models to account for variability. Higher baseline blood pressure predicted larger reductions.
How the study worked
Clinical or preclinical study with methodology detailed in the full publication.
Who was studied
Adults in clinical trials receiving subcutaneous semaglutide for various indications
What this study cannot tell us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
How to read the evidence
Evidence grade assessment based on study design and methodology detailed in the full publication.
When this study was published
Published in 2025. Reflects current state of peptide therapeutic research.
The bigger picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
Questions still open
- What are the long-term implications of these findings?
- How do these results compare to other studies in this area?
- What further research is needed to confirm and extend these findings?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.
Journal of endocrinological investigation, 48(2), 283-294
Citation
Ala, Moein; Moheb Aleaba, Mohammadreza. (2025). The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.. Journal of endocrinological investigation, 48(2), 283-294. https://doi.org/10.1007/s40618-024-02459-3